Industry News

9 July 2025

Lupin and Zentiva Sign License and Supply Agreement for Commercializing Certolizumab

Lupin Limited and Zentiva Group , a pan-European pharmaceutical company, have entered into a license and supply agreement for commercialization of Lupins biosimilar Certolizumab Pegol, across multiple markets globally.
7 July 2025

Biocon Biologics secures UK MHRA approval for Denosumab biosimilars Vevzuo® and Evfraxy®

Biocon Biologics Ltd. (BBL), a global biosimilars company and subsidiary of Biocon Ltd., has announced that the UKs Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisations for its Denosumab biosimilars, Vevzuo® and Evfraxy
5 July 2025

Lupin launches Ipratropium Bromide Nasal Solution (Nasal Spray) in the United States

Global pharma major Lupin Limited announced the launch of Ipratropium Bromide Nasal Solution (Nasal Spray), 0.03% and 0.06%, in the United States.
3 July 2025

Novartis shares phase III GCAptAIN trial results: Cosentyx falls short of primary goal in treating Giant Cell Arteritis

Novartis has announced the top-line results of its Phase III GCAptAIN study, evaluating Cosentyx (secukinumab) in patients with giant cell arteritis (GCA) a serious inflammatory condition that primarily affects adults over the age of 50.
2 July 2025

European Commission Approves Vertex’s Next-Generation Cystic Fibrosis Therapy, ALYFTREK®

Vertex Pharmaceuticals has announced that the European Commission has approved its newest cystic fibrosis treatment, ALYFTREK a once-daily, triple-combination therapy made up of deutivacaftor, tezacaftor, and vanzacaftor.
1 July 2025

Biological E. and Recbio partner to bring HPV9 Vaccine to India and global markets

In a significant development for global health, Hyderabad-based Biological E. Limited has joined hands with Chinese biopharmaceutical firm Jiangsu Recbio Technology Company Limited to produce and distribute the 9-valent Human Papillomavirus (HPV9) vaccine, REC603.
1 July 2025

Alembic Pharmaceuticals receives final USFDA approval for Doxorubicin Hydrochloride Liposome Injection

Alembic Pharmaceuticals Limited has announced that it has received final approval from the U.S. Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Doxorubicin Hydrochloride Liposome Injection in two strengths: 20 mg/10 mL (2 mg/mL) and 50 mg/25 mL (2 mg/mL) single-dose vials.
26 June 2025

Eli Lilly Launches Mounjaro KwikPen in India to Rival Novo Nordisk Wegovy

As reported by Reuters, U.S. pharmaceutical giant Eli Lilly has launched its Mounjaro KwikPen in India, expanding its portfolio of treatments for diabetes and obesity.
26 June 2025

Lupin Launches Generic Prucalopride Tablets in U.S. for Chronic Constipation Treatment

Lupin Limited, a leading global pharmaceutical company, has announced the launch of its Prucalopride Tablets in 1 mg and 2 mg strengths in the United States, following the recent approval of its Abbreviated New Drug Application (ANDA) by the U.S. Food and Drug Administration (FDA).
26 June 2025

Glenmark Pharmaceuticals launches TEVIMBRA® in India, boosting access to advanced Immuno-Oncology treatments

Glenmark Pharmaceuticals Ltd., a research-driven global pharmaceutical company, has announced the launch of TEVIMBRA® (tislelizumab) in India, marking its official entry into the immuno-oncology segment.